EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective

Vladimir Volloch, Sophia Rits-Volloch

Journal of Alzheimer’s Disease · 2023

DOI: 10.3233/jad-230164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2023. Verfasst von Vladimir Volloch und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In clinical trials, lecanemab and donanemab showed statistically significant yet marginal slowdown of Alzheimer’s disease (AD)-associated cognitive decline. This could be due to their sub-optimal design and/or deployment; alternatively, their limited efficiency could be intrinsic. Distinguishing between the two is of great importance considering the acute need of efficient AD therapy and tremendous resources being invested in its pursuit. The present study analyzes the mode of operation of lecanemab and donanemab within the framework of recently proposed Amyloid Cascade Hypothesis 2.0 and concludes that the second possibility is correct. It suggests that substantial improvement of the efficiency of these drugs in symptomatic AD is unlikely and proposes the alternative therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloid beta-PeptidesAmyloidAmyloidogenic ProteinsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid Cascade Hypothesis 2.0AβPP-independent iAβ generation in ADdonanemabintraneuronal Aβlecanemab

Substanzen

Amyloid beta-PeptidesAmyloidAmyloidogenic ProteinslecanemabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.
  • Division of Molecular Medicine, Children's Hospital, Boston, MA, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Förderung

  • NIGMS NIH HHS
  • NIAMS NIH HHS

Zitieren

APA

Volloch, V., & Rits-Volloch, S. (2023). Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-230164

Vancouver

Volloch V, Rits-Volloch S. Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective. Journal of Alzheimer’s Disease. 2023. doi:10.3233/jad-230164

BibTeX
@article{Volloch2023,
  author = {Volloch, Vladimir and Rits-Volloch, Sophia},
  title = {Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective},
  journal = {Journal of Alzheimer’s Disease},
  year = {2023},
  doi = {10.3233/jad-230164}
}
Kostenlos starten →